Daratumumab in AL Amyloidosis: A Real-Life Experience of the “RTM” (Regional Tuscan Myeloma Network)

Daratumumab in AL Amyloidosis: A Real-Life Experience of the “RTM” (Regional Tuscan Myeloma Network)

Systemic amyloidosis arises from monoclonal CD38+ plasma cells that produce misfolded immunoglobulin light chains, which form amyloid fibrils that are deposited into different tissues, leading to organ damage. Daratumumab is a human IgG/k monoclonal antibody that targets CD38, a glycoprotein uniform...

Full description

Bibliographic Details
Main Authors: Vincenzo Sammartano, Elisabetta Antonioli, Gabriele Buda, Sara Ciofini, Veronica Candi, Ludovica Pengue, Maria Livia Del Giudice, Irene Attucci, Francesca Bacchiarri, Ubaldo Occhini, Maria Teresa Pirrotta, Federico Perfetto, Monica Bocchia, Alessandro Gozzetti
Format: Article
Language:English
Published: MDPI AG 2022-03-01
Series:Journal of Personalized Medicine
Subjects:
amyloidosis
real-life
daratumumab
multiple myeloma
Online Access:https://www.mdpi.com/2075-4426/12/3/484

Internet

https://www.mdpi.com/2075-4426/12/3/484

Similar Items